Potential blockbusters and root-cause treatments from Eli Lilly, Merck, Takeda and others could get a regulatory nod this ...

The FDA has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1).

Alkermes (ALKS) announced that the FDA has granted Breakthrough Therapy Designation to alixorexton, a novel, investigational, ...

The latest announcement is out from Alkermes ( (ALKS) ).

Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the treatment of narcolepsy type 1 (NT1), ...

The biopharmaceutical company accepted for filing a supplemental new drug application for AXS-05 to treat Alzheimer's disease agitation, and has granted the application priority review designation, ...

Data suggest that pitolisant, a histamine 3-receptor antagonist/inverse agonist under development for narcolepsy treatment, showed limited abuse potential and other benefits, according to findings ...

Nina Shand couldn’t stay awake. She had taken afternoon naps since she was a teenager to accommodate her “work hard, play hard” attitude, but when she was in her mid-20s the sleepiness became more ...

The FDA has accepted for filing with priority review Jazz Pharmaceuticals’ new drug application for JZP-258. The investigational medicine targets cataplexy and excessive daytime sleepiness associated ...

DUBLIN--(BUSINESS WIRE)--The "Global Narcolepsy Drugs Market (By Therapeutic Type, Disease Type, End User, Regional Analysis), Pipeline Analysis, Key Company Profiles and Recent Developments - ...

Increase in prevalence of narcolepsy across the globe, surge in narcolepsy awareness programs, and presence of reimbursement policies regarding narcolepsy are expected to propel the growth of the ...

DUBLIN--(BUSINESS WIRE)--The "Narcolepsy Drugs Market by Disease Type and Therapeutics Type: Global Opportunity Analysis and Industry Forecast, 2019-2026" report has been added to ...